Business
American Healthcare REIT owns clinical healthcare real estate focused on senior housing, skilled nursing facilities, outpatient medical buildings, and related facilities.
American Healthcare REIT grew revenue, swung to net income, and expanded equity, while dividends rose.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical healthcare real estate REITNote
- Revenue — Revenue +11.2% to $2.095BOK
- Profitability — Net income turned positive at $69.8MOK
- Cash flow — Cash from operations +67.2% to $294.4MOK
- Dividends — Dividends +35.3% to $163.5MNote
- Insiders — 0 buys / 6 sellsWatch
- Accounting — Real-estate impairment was the key audit matterWatch
Where the revenue comes from
Fiscal 2025, as American Healthcare REIT, Inc. reports it. History and quarterly detail are in the app.
- Integrated Senior Health Campuses$1.8B
- SHOP$330.6M
- Outpatient Medical$126.1M
- Triple Net Leased Properties$39.5M
Leadership changes
From American Healthcare REIT, Inc.'s own filings, the day they're filed.
- Jeffrey Hanson · Chief Executive Officer · appointmenteff. 2026-07-21
- Gabe Willhite · Chief Operating Officer · appointmenteff. 2026-07-21
- Scott A. Estes · Director · appointmenteff. 2026-07-21
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-08-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about American Healthcare REIT, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.